Thioredoxin Systems

Executive Summary

Thioredoxin Systems AB is a Swedish biotechnology company founded in 2016, focused on developing novel antibacterial therapies to combat antimicrobial resistance (AMR). The company's lead program, EbsArgent™, is an innovative antibiotic combination that targets the bacterial thioredoxin system, a redox pathway essential for bacterial survival and virulence. This mechanism is distinct from conventional antibiotics, offering a promising approach to treating complicated urinary tract infections (cUTIs) caused by multidrug-resistant (MDR) pathogens. By disrupting thioredoxin-dependent processes, EbsArgent has the potential to overcome common resistance mechanisms and provide a new treatment option for infections that are increasingly difficult to manage with existing drugs. The company's technology is built on pioneering redox biology research, positioning it at the forefront of the AMR crisis. While Thioredoxin Systems is still in the early stages of development, its unique target and the urgent need for new antibiotics create significant potential. Upcoming milestones include advancing EbsArgent through preclinical trials and initiating first-in-human studies, which will be critical for validating its safety and efficacy. The company may also seek partnerships or funding to support clinical development. With AMR posing a growing global health threat, Thioredoxin Systems represents a promising investment opportunity in the antibiotic pipeline.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 1 Clinical Trial for EbsArgent60% success
• Q1 2027Strategic Partnership or Licensing Deal50% success
• Q3 2026Grant or Non-Dilutive Funding Award70% success